Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

258
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
258
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

299
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
299
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

284
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
284
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

271
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
271
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

254
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
254
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.2K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Update on Non-Biological and RNA-Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper.

Allergy·2026
Same author

Vertical heterostructure of graphite-MoS<sub>2</sub> for gas sensing.

Nanoscale horizons·2024
Same author

Metabolic pathways in immune senescence and inflammaging: Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology.

Allergy·2023
Same author

Matrix Gla Protein drives stemness and tumor initiation in ovarian cancer.

Cell death & disease·2023
Same author

Compositional and Morphological Characterization of 'Sorrento' and 'Chandler' Walnuts.

Foods (Basel, Switzerland)·2022
Same author

Temporin G, an amphibian antimicrobial peptide against influenza and parainfluenza respiratory viruses: Insights into biological activity and mechanism of action.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2021
Same journal

Differences in Reported Anaphylaxis Associated With Common Nonsteroidal Anti-inflammatory Drugs: A Pharmacovigilance Study.

International archives of allergy and immunology·2026
Same journal

Association of Serum Galectin-3 Binding Protein with Acute Exacerbation, Inflammation, and Airway Remodeling in Pediatric Asthma.

International archives of allergy and immunology·2026
Same journal

Effectiveness of a Provincial Law to Improve Epinephrine Use for Anaphylaxis in Schools in Alberta, Canada: A Pre-Post Study.

International archives of allergy and immunology·2026
Same journal

Rab27 a regulates dendritic cell immune tolerogenic capacity.

International archives of allergy and immunology·2026
Same journal

Burden of Hereditary Angioedema in Adults: Impact of Disease and Patient Characteristics.

International archives of allergy and immunology·2026
Same journal

Predictors of Treatment Response to Omalizumab in Children with Chronic Spontaneous Urticaria: A Real World Study.

International archives of allergy and immunology·2026
See all related articles

Related Experiment Video

Updated: Nov 1, 2025

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
07:50

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

14.5K

Anti-Inflammatory Effect of Deflazacort.

C Stellato, V Casolaro, A Renda

    International Archives of Allergy and Immunology
    |June 25, 2021
    PubMed
    Summary
    This summary is machine-generated.

    Deflazacort (DFZ) effectively inhibits IgE-mediated release of histamine and leukotriene C4 (LTC4) from basophils, showing comparable efficacy to dexamethasone and prednisolone. DFZ also demonstrated additive effects when combined with cyclosporin A.

    Keywords:
    BasophilsCorticosteroidsCyclosporin ADeflazacortHistamineLeukotriene C4

    More Related Videos

    Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
    08:02

    Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids

    Published on: April 25, 2016

    9.9K
    Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
    08:58

    Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

    Published on: January 5, 2017

    12.5K

    Related Experiment Videos

    Last Updated: Nov 1, 2025

    Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
    07:50

    Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

    Published on: July 16, 2012

    14.5K
    Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
    08:02

    Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids

    Published on: April 25, 2016

    9.9K
    Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
    08:58

    Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

    Published on: January 5, 2017

    12.5K

    Area of Science:

    • Immunology
    • Pharmacology

    Background:

    • Glucocorticoids are widely used for their anti-inflammatory properties.
    • Understanding the comparative efficacy of different glucocorticoids is crucial for optimizing treatment.
    • Basophils play a key role in allergic responses through mediator release.

    Purpose of the Study:

    • To compare the effects of deflazacort (DFZ), prednisolone (PRED), and dexamethasone (DEX) on IgE-mediated mediator release from human basophils.
    • To evaluate the combined effects of DFZ and cyclosporin A (CsA) on basophil mediator release.

    Main Methods:

    • Human peripheral blood basophils were incubated with pharmacological concentrations of DFZ, PRED, and DEX.
    • The release of preformed (histamine) and de novo synthesized (leukotriene C4 - LTC4) mediators was measured.
    • Basophils were also incubated with DFZ in combination with CsA.

    Main Results:

    • DFZ concentration-dependently inhibited IgE-dependent histamine and LTC4 release from basophils (9-50%).
    • DFZ exhibited similar anti-inflammatory efficacy to DEX and comparable efficacy and potency to PRED.
    • Low concentrations of DFZ combined with CsA produced an additive inhibition of histamine and LTC4 release.

    Conclusions:

    • Deflazacort is an effective inhibitor of key inflammatory mediators released by basophils.
    • DFZ demonstrates comparable anti-inflammatory activity to other established glucocorticoids.
    • The additive effect of DFZ with CsA suggests potential synergistic therapeutic benefits in allergic conditions.